< Back to latest news & events

News

Coronavirus update: Oral proceedings before Opposition Divisions and Boards of Appeal

August 2020

In view of the ongoing disruptions caused by the spread of Coronavirus (COVID-19), the European Patent Office (EPO) has implemented special measures for arrangement and conduct of oral proceedings. These measures are now updated with respect to oral proceedings before Opposition Divisions and Boards of Appeal. Oral proceedings in examination will continue to be held by videoconference.

Oral proceedings before Opposition Divisions

The EPO has decided to postpone oral proceedings in opposition scheduled until 31 December 2020 (previously until 14 September 2020).

Cases affected are those that have not already been confirmed to take place by videoconference or will be held by videoconference with the parties’ consent under the Pilot Project for oral proceedings. Under the Pilot Project (Article 2 of the Decision of the President of the EPO dated 14 April 2020) oral proceedings before Opposition Divisions may be held by videoconference at the discretion of the Opposition Division and with the agreement of all parties. The parties will be informed about the postponement of oral proceedings in affected cases as soon as possible.

The EPO intends to maintain oral proceedings in opposition which have been scheduled to take place on the premises of the EPO on or after 4 January 2021.

Oral proceedings before Boards of Appeal

The EPO has also decided to discontinue the recently introduced practice of contacting parties to enquire whether they are able to attend oral proceedings before the Boards of Appeal. If parties cannot attend oral proceedings for which they have been summoned, they will now have to request a change of date (Article 15(2) RPBA 2020).

In addition, owing to the need for physical distancing, venues and/or starting times for oral proceedings may be changed without informing parties. As such, changes may take place at short notice, and it is up to the parties to consult the online calendar approximately three days before their oral proceedings to check whether they will take place on the Haar premises or in the Isar building and when exactly they are scheduled to start.

See the official notice here.

This update was prepared by HGF Senior European Patent Attorney Dr Alex Colman. If you would like further advice on this or any other matter, please contact Alex.  Alternatively, you can contact your usual HGF representative or visit our Contact page to get in touch with your nearest HGF office.

Latest updates

Polymorphs: Clearing the Inventive Step Hurdle at the European Patent Office (EPO)

Polymorphic forms of active pharmaceutical ingredients (APIs) can represent commercially valuable compound subject matter and can be critical to providing necessary drug product characteristics and performance. However, patenting polymorphs is …

Read article

IQPC Global US Exchange

HGF are proud ‘Silver Plus’ sponsors of the IQPC Global US Exchange, at the Austin Marriot South, Texas. The IQPC Global US Exchange will be held at the Austin Marriot …

Read article

Update on the Precision Breeding Act 2023: details emerge of the new simplified regulatory pathway for gene edited plant and animal derived food and feed products

The Genetic Technology (Precision Breeding) Act 2023 could come into force as early as spring 2025. It empowers the Food Standards Agency (FSA) to create a new simplified regulatory pathway …

Read article

Court of Appeal Decision Upholds Invalidity of Patent Due to Amendment Identifying Embodiment as Outside the Scope of the Claims

In a case that highlights the challenges arising due to post-grant amendments, and in particular interpretation of the claims in view of the description, the Court of Appeal in Ensygnia …

Read article

UPC Court of Appeal clarifies approach for interpreting claims with “obvious” errors

Alexion Pharmaceuticals, Inc. v Samsung Bioepis NL B.V. [UPC_CoA_402/2024] –Court of Appeal of the UPC (Grabinski, Blok, Gougé, Enderlin, Hedberg) – 20 December 2024 Alexion Pharmaceuticals, Inc. v Amgen Technology …

Read article

IP Ingredients: Winter Case Law Review 2024

As the nights draw in and the frenzy to finish everything off before the holiday season reaches its peak, it’s time to take a break, grab your favourite hot beverage …

Read article